Top Clinical Research Informer Drugs Genomics Content for Sat.Aug 07, 2021

Increase in extreme precipitation in the northeast caused by Atlantic variability and climate change

Scienmag

AUGUST 7, 2021

Results explain the increase in heavy rain and snow events across the northeast Credit: Figure by Huanping Huang. Recent record-breaking rainfall across the northeastern United States is part of a larger trend. From Maine to West Virginia, the Northeast has seen an abrupt increase in extreme precipitation– heavy rain and snow resulting in about 1″–2″ […].

3 Common But Serious Informed Consent Issues In Clinical Research

Clinical Trial Gurus

AUGUST 7, 2021

Informed Consent is arguably the most critical assessment in all of clinical research. In this video I give a few examples of some critical informed consent errors I have encountered during my career.

Clinical Research

Clinical Research Research

Novo Nordisk’s net profit increased by 10% in the first six months of 2021

The Pharma Data

AUGUST 7, 2021

Operating profit decreased by 1% in Danish kroner and increased by 9% at constant exchange rates (CER). Sales increased by 5% in Danish kroner and by 12% at CER to DKK 66.8 billion. Sales in International Operations increased by 7% in Danish kroner (13% at CER), and sales in North America Operations increased by 1% in Danish kroner (11% at CER). Sales within Diabetes and Obesity care increased by 5% in Danish kroner to DKK 56.9 billion (13% at CER), driven by GLP-1 growth of 21% in Danish kroner

Sales

Sales Drugs

Core One Labs to Move Its Psychedelic Formulations for the Treatment of Stroke and Depression Toward Clinical Development

BioTech 365

AUGUST 7, 2021

Core One Labs to Move Its Psychedelic Formulations for the Treatment of Stroke and Depression Toward Clinical Development Core One Labs to Move Its Psychedelic Formulations for the Treatment of Stroke and Depression Toward Clinical Development VANCOUVER, British Columbia, Aug.

Clinical Development

Clinical Development Development

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

Clinical Supply

Bayer strengthens drug discovery platform through acquisition of Vividion Therapeutics

The Pharma Data

AUGUST 7, 2021

Acquisition strengthens Bayer’s drug discovery capabilities with cutting-edge chemoproteomics platform / Vividion’s unique approach identifies previously unknown binding pockets in undruggable targets to generate first-in-class novel compounds in indications of high unmet medical need / Vividion’s technology has already proven its applicability pre-clinically in oncology and immune-related diseases, with potential to expand into additional therapeutic areas / Vividion to operate autonomously and

Drugs

Drugs Protein Genome Genomics

Future drug patent expirations by year

Drug Patent Watch

AUGUST 7, 2021

Pharmaceutical drug patents enable branded drug companies to prevent market entry by competitors until the patents expire. The term of drug patents varies. The basic term for a patent is…. The post Future drug patent expirations by year appeared first on DrugPatentWatch - Make Better Decisions.

Drugs

Drugs Branding Marketing

FDA approves Nexviazyme® (avalglucosidase alfa-ngpt), an important new treatment option for late-onset Pompe disease

The Pharma Data

AUGUST 7, 2021

Approval is based on positive Phase 3 data demonstrating improvements in key disease burden measures and establishing its safety profile Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells. The U.S. Food and Drug Administration (FDA) has approved Nexviazyme® (avalglucosidase alfa-ngpt) for the treatment of patients one year of age and older with late-onset Pompe disease, a progressive and debilit

FDA Approval

FDA Approval Medicine Trials Clinical Trials

FDA approves Nexviazyme® (avalglucosidase alfa-ngpt), an important new treatment option for late-onset Pompe disease

The Pharma Data

AUGUST 7, 2021

Approval is based on positive Phase 3 data demonstrating improvements in key disease burden measures and establishing its safety profile Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells. The U.S. Food and Drug Administration (FDA) has approved Nexviazyme® (avalglucosidase alfa-ngpt) for the treatment of patients one year of age and older with late-onset Pompe disease, a progressive and debilit

FDA Approval

FDA Approval Medicine Trials Clinical Trials

Takeda Updates its Q1 FY2021 Earnings Materials to Reflect Impact of Decision by the Irish Tax Appeals Commission Relating to Tax Assessment on Break Fee Shire Received from AbbVie

The Pharma Data

AUGUST 7, 2021

today announced that it re-filed its “Summary of Financial Statements for the Three-month Period Ended June 30, 2021 (IFRS, Consolidated)” to the Tokyo Stock Exchange, which was revised to reflect the impact of a subsequent event that occurred on July 30, 2021 on the consolidated financial statements for the fiscal quarter ended on June 30, 2021 (“Q1 FY2021”).

Clinical Research Informer

Sat.Aug 07, 2021

Increase in extreme precipitation in the northeast caused by Atlantic variability and climate change

3 Common But Serious Informed Consent Issues In Clinical Research

Trending Sources

Novo Nordisk’s net profit increased by 10% in the first six months of 2021

Core One Labs to Move Its Psychedelic Formulations for the Treatment of Stroke and Depression Toward Clinical Development

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

Bayer strengthens drug discovery platform through acquisition of Vividion Therapeutics

Future drug patent expirations by year

FDA approves Nexviazyme® (avalglucosidase alfa-ngpt), an important new treatment option for late-onset Pompe disease

FDA approves Nexviazyme® (avalglucosidase alfa-ngpt), an important new treatment option for late-onset Pompe disease

Takeda Updates its Q1 FY2021 Earnings Materials to Reflect Impact of Decision by the Irish Tax Appeals Commission Relating to Tax Assessment on Break Fee Shire Received from AbbVie

Stay Connected